Betulinic Acid Induces ROS-Dependent Apoptosis and S-Phase Arrest by Inhibiting the NF-κB Pathway in Human Multiple Myeloma

Min Shen, Yiqiang Hu, Yan Yang, Lanlan Wang, Xin Yang, Bo Wang, Mei HuangOxidative 2019 · DOI

TL;DR

This study reveals that betulinic acid (BA), a natural compound, effectively combats multiple myeloma (MM) by inducing cancer cell death through a two-pronged attack: triggering apoptosis and cell cycle arrest, and crucially, by inhibiting the NF-κB pathway. This inhibition leads to an overload of reactive oxygen species (ROS), ultimately causing MM cell demise, suggesting BA as a promising therapeutic agent.

What Problem Does This Paper Address?

Multiple myeloma (MM) is a challenging hematological malignancy characterized by drug resistance and evasion of apoptosis, making it difficult to treat effectively. While betulinic acid (BA) has shown promise against various cancers, its specific mechanisms and efficacy against MM were not well understood. This paper aims to elucidate how BA exerts its anti-MM effects, focusing on its impact on cell death pathways, cell cycle regulation, and the interplay between reactive oxygen species (ROS) and the NF-κB signaling pathway, a known player in cancer progression and inflammation.

Methods

The researchers employed a multi-faceted approach to investigate BA's effects on MM cells, both in vitro and in vivo. Key techniques included:

  • Cell viability and proliferation assays: CCK-8 and EdU staining were used to quantify how BA affects cancer cell survival and their ability to divide.
  • Apoptosis detection: Hoechst 33342 staining, Annexin V/PI double staining, and Western blotting for apoptosis-related proteins (Bax, Bcl-2, cleaved caspases, PARP1) were used to assess programmed cell death.
  • Cell cycle analysis: Flow cytometry was used to determine how BA influences the progression of cells through different stages of the cell cycle, specifically looking for S-phase arrest.
  • Mitochondrial membrane potential (MMP) assessment: JC-1 staining was employed to evaluate the integrity of mitochondria, a key organelle in apoptosis.
  • ROS measurement: DCFH-DA staining and flow cytometry were used to quantify intracellular ROS levels.
  • Western blotting and immunofluorescence: These techniques were used to assess the expression and localization of key proteins involved in the NF-κB pathway (NF-κB p65, p-NF-κB p65, IKKα/β, IκBα, p-IκBα).
  • Real-time PCR: This was used to examine the mRNA expression levels of genes involved in ROS regulation.
  • Nude mouse xenograft model: In vivo studies were conducted using mice with implanted human MM tumors to evaluate BA's anti-tumor efficacy and its effects on tumor growth, proliferation (Ki-67), and NF-κB signaling.

Datasets

Not discussed in the paper. The study primarily relies on experiments conducted using established human MM cell lines (U266 and RPMI 8226) and a xenograft mouse model.

Key Insights and Ideas

  • BA's dual action: BA doesn't just kill MM cells; it does so through multiple coordinated mechanisms, including apoptosis and cell cycle arrest, making it a robust anti-cancer agent.
  • ROS as a critical mediator: The study strongly implicates ROS overproduction as a central driver of BA-induced cell death. This highlights the delicate balance of redox homeostasis in cancer cells and how disrupting it can be a potent therapeutic strategy.
  • NF-κB as a key target: The research uncovers that BA's ability to inhibit the constitutively active NF-κB pathway in MM is fundamental to its action. This is significant because NF-κB is often dysregulated in cancers and promotes survival and proliferation.
  • The NF-κB-ROS connection: A crucial finding is the direct link between NF-κB inhibition and ROS accumulation. This suggests that by suppressing NF-κB, BA indirectly promotes oxidative stress, which then drives apoptosis.
  • S-phase arrest specificity: BA's ability to induce S-phase arrest, rather than arrest at other cell cycle checkpoints, is a specific mechanism that warrants further investigation for targeted therapies.

Key Results

  • Morphological changes and apoptosis: BA treatment led to visible signs of cell death, including shrinkage and nuclear condensation, and significantly increased apoptosis rates in MM cells in a dose- and time-dependent manner.
  • Inhibition of proliferation: BA effectively reduced MM cell viability and proliferation, as evidenced by CCK-8 and EdU assays.
  • Mitochondrial pathway activation: BA treatment resulted in the downregulation of anti-apoptotic protein Bcl-2, upregulation of pro-apoptotic protein Bax, and the release of cytochrome c, activating the caspase cascade and leading to apoptosis.
  • S-phase arrest: BA induced a significant accumulation of cells in the S-phase of the cell cycle, accompanied by changes in key cell cycle regulatory proteins (decreased cyclin A and CDK2, increased p21Waf1/Cip1 and p27Kip).
  • MMP collapse: BA caused a concentration-dependent decrease in mitochondrial membrane potential, a hallmark of early apoptosis.
  • ROS overproduction: BA treatment led to a significant increase in intracellular ROS levels, which was partially reversed by the ROS scavenger N-acetyl cysteine (NAC), indicating ROS's pivotal role in BA-induced apoptosis.
  • NF-κB inhibition: BA markedly reduced the expression and activation of NF-κB p65 and its upstream regulators (IKKα/β), both in vitro and in vivo.
  • Tumor growth inhibition: In a xenograft mouse model, BA significantly suppressed tumor growth, reduced tumor weight, and decreased cellular proliferation (Ki-67) and NF-κB p65 expression in tumor tissues.

Limitations and Future Work

The authors acknowledge that while their study provides significant insights into BA's mechanisms against MM, further research is warranted. Specifically, they suggest that:

  • Broader mechanisms: Further studies are needed to fully explore the broader mechanisms underlying BA's effects on MM.
  • Drug safety: Investigations into the drug safety profile of BA are crucial before clinical applications can be considered.
  • Clinical translation: While promising, the transition from preclinical findings to clinical trials requires extensive validation.

The study's findings strongly support BA as a potential therapeutic agent for MM, particularly due to its ability to disrupt redox homeostasis by inhibiting the NF-κB pathway, leading to ROS-mediated cell death.

Summary updated

Abstract

Betulinic acid (BA), as a prospective natural compound, shows outstanding antitumor bioactivities against many solid malignancies. However, its mechanism against multiple myeloma (MM) remains elusive. Herein, for the first time, we studied the antitumor activity of BA against MM both <i>in vivo</i> and <i>in vitro</i>. We showed that BA mediated cytotoxicity in MM cells through apoptosis, S-phase arrest, mitochondrial membrane potential (MMP) collapse, and overwhelming reactive oxygen species (ROS) accumulation. Moreover, when the ROS scavenger N-acetyl cysteine (NAC) effectively abated elevated ROS, the BA-induced apoptosis was partially reversed. Our results revealed that BA-mediated ROS overproduction played a pivotal role in anticancer activity. Molecularly, we found that BA resulted in marked inhibition of the aberrantly activated NF-<i>κ</i>B pathway in MM. As demonstrated by using the NF-<i>κ</i>B pathway-specific activator TNF-<i>α</i> and the inhibitor BAY 11-7082, BA-mediated inhibition of the NF-<i>κ</i>B pathway directly promoted the overproduction of ROS and, ultimately, cell death. Furthermore, BA also exerted enormous tumor-inhibitory effects via repressing proliferation and inhibiting the NF-<i>κ</i>B pathway in our xenograft model. Overall, by blocking the NF-<i>κ</i>B pathway that breaks redox homeostasis, BA, as a potent NF-<i>κ</i>B inhibitor, is a promising therapeutic alternative for MM.
BibTeX
@inproceedings{shen2019betulinic,
  author = {Min Shen and Yiqiang Hu and Yan Yang and Lanlan Wang and Xin Yang and Bo Wang and Mei Huang},
  title = {{Betulinic Acid Induces ROS-Dependent Apoptosis and S-Phase Arrest by Inhibiting the NF-<i>κ</i>B Pathway in Human Multiple Myeloma}},
  booktitle = {Oxidative},
  year = {2019},
  doi = {10.1155/2019/5083158},
}
Figure